Skip to main content
Clinical Trials/DRKS00017218
DRKS00017218
Completed
Not Applicable

Prospective, non-interventional, open-label study on the prophylactic use of a pegylated filgrastim (Pelgraz®) to reduce the duration of neutropenia and the incidence of febrile neutropenia under conventional chemotherapy for the treatment of haematological malignancies and solid tumors - PROOF

ACCORD Healthcare GmbH0 sites1,665 target enrollmentMay 29, 2019

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
febrile neutropenia
Sponsor
ACCORD Healthcare GmbH
Enrollment
1665
Status
Completed
Last Updated
last year

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
May 29, 2019
End Date
July 5, 2023
Last Updated
last year
Study Type
Observational
Sex
All

Investigators

Eligibility Criteria

Inclusion Criteria

  • Male or female patients \=18 years with haematological malignancies or solid tumors who receive a conventional cytotoxic chemotherapy and who are treated prophylactically with Pelgraz® according to the SmPC.
  • Risk of febrile neutropenia between \= 10% and 20% (with individual risk factors) as assessed by the attending physician or overall FN risk of \> 20%.
  • Written informed consent given by the patient or by relatives / caregivers for the retro\- and prospective collection, transfer and analysis of pseudonymized data as well as for verification of patient data during a monitoring visit.

Exclusion Criteria

  • Hypersensitivity to pegfilgrastim or to any other ingredient of Pelgraz®
  • Patients with severe congenital neutropenia who develop leukemia or who show signs of leukemia
  • Patients with myelodysplasia or chronic myelotic leukaemia
  • Patients with a recent history of pulmonary infiltrates or pneumonia
  • For female patients: pregnancy or breastfeeding

Outcomes

Primary Outcomes

Not specified

Similar Trials